NLS Pharmaceutics AG reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was USD 7.61 million compared to USD 8.64 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.54 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.189 USD | -6.34% | -12.86% | -67.96% |
Jun. 28 | NLS Pharmaceutics Announces Registered Direct Offering, Private Placement of Shares, Warrants | MT |
Jun. 27 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
1st Jan change | Capi. | |
---|---|---|
-67.96% | 7.59M | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- NLSP Stock
- News NLS Pharmaceutics AG
- NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2023